The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE −/− mouse model
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
Liraglutide, a once-daily glucagon-like peptide-1 receptor (GLP-1R) agonist, has been approved as a new treatment for type 2 diabetes and is the subject of a clinical trial programme to evaluate the effects on cardiovascular disease and safety. The current study aimed to determine the in vivo effect of liraglutide on progression of atherosclerotic vascular disease in the apolipoprotein E-deficient (ApoE −/− ) mouse model and identify underlying mechanisms responsible. Liraglutide treatment inhibited progression of early onset, low-burden atherosclerotic disease in a partially GLP-1R-dependent manner in the ApoE −/− mouse model. In addition, liraglutide treatment inhibited progression of atherosclerotic plaque formation and enhanced plaque stability, again in a partially GLP-1R-dependent manner. No significant effect of liraglutide on progression of late onset, high-burden atherosclerotic disease was observed. In addition, no significant endothelial cell dysfunction was identified in ApoE −/− mice with early onset, low-burden atherosclerotic disease, although significant prevention of weight gain was observed in liraglutide-treated mice using this dietary protocol. Taken together, these results suggest a potential role for liraglutide in the prevention and stabilisation of atherosclerotic vascular disease together with possible protection against major cardiovascular events.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
1 retracted
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183
RetractedNaghavi, M., Libby, P., Falk, E., Casscells, S. W., Litovsky, S., Rumberger, J., Badimon, J. J., Stefanadis, C., Moreno, P., Pasterkamp, G., et al. (2003) · Circulation · doi:10.1161/01.cir.0000087481.55887.c9 · Cited by 2,668
Naghavi, M., Libby, P., Falk, E., Casscells, S. W., Litovsky, S., Rumberger, J., Badimon, J. J., Stefanadis, C., Moreno, P., Pasterkamp, G., et al. (2003) · Circulation · doi:10.1161/01.cir.0000087480.94275.97 · Cited by 2,270
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824 · cited 2×
“Specifically, cryocut cross sections (5 μm) of the BCA were prepared, and two sections (20 μm apart) for each mouse were stained routinely with (1) oil red O (0.”
MethodNyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680
Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548
Panjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1937 · Cited by 346
Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats
Yu, M., Moreno, C., Hoagland, K. M., Dahly, A., Ditter, K., Mistry, M., & Roman, R. J. (2003) · Journal of Hypertension · doi:10.1097/00004872-200306000-00012 · Cited by 273
Nagashima, M., Watanabe, T., Terasaki, M., Tomoyasu, M., Nohtomi, K., Kim-Kaneyama, J., Miyazaki, A., & Hirano, T. (2011) · Diabetologia · doi:10.1007/s00125-011-2241-2 · Cited by 259
Gaspari, T., Liu, H., Welungoda, I., Hu, Y., Widdop, R. E., Knudsen, L. B., Simpson, R. W., & Dear, A. E. (2011) · Diabetes and Vascular Disease Research · doi:10.1177/1479164111404257 · Cited by 202
Self-citation
Cited by
Items 101–155 of 155
Zhou, Y., Yuan, Z., Wang, M., Zhang, Z., Tan, C., Yu, J., Bi, Y., Liao, X., Zhou, X., Sheikh, M. S. A., et al. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10090386 · Cited by 12
Effect of Liraglutide on Vascular Inflammation Evaluated by [64Cu]DOTATATE
Zobel, E. H., Ripa, R. S., von Scholten, B. J., Curovic, V. R., Díaz, L. J., Hansen, T. W., Rossing, P. R., & Kjær, A. (2021) · Diagnostics · doi:10.3390/diagnostics11081431 · Cited by 12
Tong, L., Ju, Z., Wang, L., Qiu, J., Liu, L., Zhou, X., Liang, T., Geng, D., & Zhou, S. (2019) · Journal of Functional Foods · doi:10.1016/j.jff.2019.103582 · Cited by 12
Role of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) in Patients with Chronic Heart Failure
Llongueras-Espí, P., García‐Romero, E., Colet, J. C., & González‐Costello, J. (2025) · Biomolecules · doi:10.3390/biom15091342 · Cited by 11
Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients
Madsbad, S. (2019) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1615444 · Cited by 11
SGLT2 Inhibitors and GLP-1 Receptor Agonists in PAD: A State-of-the-Art Review
Caturano, A., D’Ardes, D., Simeone, P., Lessiani, G., Gregorio, N. D., Andreetto, L., Grassi, D., Serra, C., Santilli, F., Guagnano, M. T., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155549 · Cited by 10
Heinsen, L. J., Pararajasingam, G., Andersen, T. R., Auscher, S., Sheta, H. M., Precht, H., Engdam, K. B., Hangaard, J., Lambrechtsen, J., Knop, F. K., et al. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03228-5 · Cited by 10
Song, R., Qian, H., Wang, Y., Li, Q., Li, D., Chen, J., Yang, J., Zhong, J., Yang, H., Min, X., et al. (2022) · Journal of Diabetes Research · doi:10.1155/2022/4554996 · Cited by 10
Virta, J., Hellberg, S., Liljenbäck, H., Ståhle, M. R., Silvola, J. M. U., Huusko, J., Söderström, M., Knuuti, J. M., Nuutila, P., Ylä‐Herttuala, S., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.03.029 · Cited by 10
Mansoor, M. A. (2025) · Physiologia · doi:10.3390/physiologia5030034 · Cited by 9
Diabetes and Stroke: Impact of Novel Therapies for the Treatment of Type 2 Diabetes Mellitus
Vieira, I. H., Carvalho, T., Saraiva, J. C., Gomes, L., & Paiva, I. (2024) · Biomedicines · doi:10.3390/biomedicines12051102 · Cited by 9
Tanashat, M., Al‐Ajlouni, Y. A., Abuelazm, M., Altobaishat, O., Manasrah, A., Turkmani, M. M., Khan, U., & Abouzid, M. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00726-z · Cited by 9
An Overview of Prospective Drugs for Type 1 and Type 2 Diabetes
Wu, P., Liu, Z., Jiang, X., & Fang, H. (2019) · Current Drug Targets · doi:10.2174/1389450120666191031104653 · Cited by 9
Medical and Surgical Obesity Treatments and Atherosclerosis: Mechanisms beyond Typical Risk Factors
Bostrom, J., Mottel, B. H., & Heffron, S. P. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00961-0 · Cited by 8
Anti-inflammatory effects of GLP1-RA drugs
Quintana, L., Tabaza, N., Kurt, B., & Kahles, F. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag218 · Cited by 7
Sotagliflozin: Two Birds with One Stone?
Requena-Ibáñez, J. A., Kindberg, K. M., Santos‐Gallego, C. G., Zafar, M. U., & Badimón, J. J. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07723-z · Cited by 7
Li, H., Zhang, J., Guo, Q., Xie, W. C., Zhan, X., Chen, Q., Xie, X., Sun, R., Cao, Z., Jiang, Y., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108381 · Cited by 7
Exenatide Inhibits the KCa3.1 Channels of Aortic Vascular Smooth Muscle in Diabetic Rats.
Dong, P., Liu, M., & Liu, C. (2017) · Europe PMC (PubMed Central) · doi:10.6515/acs20170612b · Cited by 6
The mechanistic role of tirzepatide in atherosclerosis: A review
Al-Kuraishy, H. M., Sulaiman, G. M., Mohammed, H. A., Saad, H. M., Waheed, H. J., Jabir, M. S., Al-Gareeb, A. I., & Albuhadily, A. K. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.147734 · Cited by 5
Dan, K., Sanada, J., Kimura, T., Iwamoto, Y., Sugisaki, T., Iwamoto, H., Fushimi, Y., Nogami, Y., Shirakiya, Y., Shimoda, M., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-42437-8 · Cited by 5
The use of glucagon-like-peptide-1 receptor agonist in the cardiology practice
Martens, P., Mathieu, C., & Vanassche, T. (2022) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2022.2076307 · Cited by 5
Zhu, Y., Zhang, W., Qu, H.-L., Zhang, Y., Zhou, R.-Q., Li, P., Wang, F., Zhang, Y., Liu, H., Li, S., et al. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i12.112423 · Cited by 4
GLP-1 Receptor Agonists: From Clinical Success to Mechanistic Insight
Patel, T., Rose, J., Katsurada, K., Yada, T., Koutakis, P., Salomon, J., Patel, K. P., & Alfaidi, M. (2026) · Circulation Research · doi:10.1161/circresaha.126.327683 · Cited by 4
The Role of Perivascular Fat in the Diagnosis and Prognosis of Atherosclerosis
Polkinghorne, M., West, H. W., & Antoniades, C. A. (2022) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2023.3.e1 · Cited by 4
High glucose promotes atherosclerosis by regulating miRNA let7d‐5p level
Wang, H., Liu, F., Zhao, W., Guo, Y., Mai, P., Zhao, S., Wen, Z., Su, J., Li, X., Wang, Y., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14180 · Cited by 4
Trusca, V. G., Fuior, E. V., & Gafencu, A. V. (2015) · Current Molecular Medicine · doi:10.2174/1566524016666151123110310 · Cited by 4
The Effect of GLP-1 Agonist Treatment On Subclinical Atherosclerosis
Sakız, D., Çalapkulu, M., Sencar, M. E., Bayram, S. M., Ünsal, İ. Ö., Kızılgül, M., Uçan, B., Özbek, M., & Çakal, E. (2022) · Van Medical Journal · doi:10.5505/vtd.2022.09815 · Cited by 3
Bile acids and incretins as modulators of obesity-associated atherosclerosis
Kirsch, A., Gindlhuber, J., Zabini, D., & Osto, E. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1510148 · Cited by 3
Vascular failure and recent anti-diabetic drugs
Oyama, J., & Node, K. (2017) · Vascular Failure · doi:10.30548/vascfail.1.1_2 · Cited by 3
Симаненкова, А. В., Макарова, М. Н., Васильевна, В. Л., Butomo, M. I., Владимировна, Д. С., & Shlyakhto, E. V. (2018) · Regional blood circulation and microcirculation · doi:10.24884/1682-6655-2018-17-2-57-63 · Cited by 3
Type 2 diabetes and cardiovascular disease: A metabolic overview of recent clinical trials
Birnbaum, Y., Ye, Y., & Bajaj, M. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.09.007 · Cited by 3
Effect of Anagliptin on Vascular Injury in the Femoral Artery of Type 2 Diabetic Rats
Noda, M., Kikuchi, C., Hori, E., Iwao, T., Nagami, C., Takeuchi, M., & Matsunaga, T. (2024) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b23-00706 · Cited by 2
Cardiovascular benefits of liraglutide in patients with type 2 diabetes: an in-depth exploration
Alluri, A. A., MITRA, A., Marepalli, A., Kshitij, R. A. J., Gandhi, N., Prystupa, Y., & Seetharaman, R. (2025) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.25.06846-2 · Cited by 1
Lamos, E. M., & Davis, S. N. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1216974 · Cited by 1
Lubberding, A. F., Holst, J. J., & Madsbad, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00017-6 · Cited by 1
Dear, A. E. (2013) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-013-6465-x · Cited by 1
Self-citationEffects of liraglutide and exenatide, two GLP-1 agonists, in vascular wall cells
Rodrigues, I. M. H. R. D. (2016) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/16zn-am61
Koshibu, M., Mori, Y., Kushima, H., Hiromura, M., Kohashi, K., Terasaki, M., Osaka, N., Fujikawa, T., Fukui, T., & Hirano, T. (2019) · The Showa University Journal of Medical Sciences · doi:10.15369/sujms.31.115
Kardiovaskuläre Effekte von GLP-1-Rezeptoragonisten
Kahles, F., & Lehrke, M. (2020) · Diabetes aktuell · doi:10.1055/a-1152-2125
Mechanisms of GLP‒1 Receptor Agonists on the Cardio-Renal Protective Effects
Kuriyama, S., & Matsumoto, K. (2022) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.53.6_249
b. Part II: Early Vascular Aging and Obesity Treatment
Jordan, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15512-3.00037-4
Giglio, R. V., Gambino, C. M., Patti, A. M., Scazzone, C., Maggio, V., MURATORE, E., Agnello, L., RIZZO, M., & Ciaccio, M. (2025) · Biochimica Clinica · doi:10.23736/s0393-0564.25.00059-7
Aktuelle Therapiekonzepte und Entwicklungen in der Diabetes mellitus Typ 2-Therapie
Honskamp, A. K. (2021) · Unipub UB Graz (Universität Graz)
Drug Repurposing: Harnessing the Therapeutics from Antidiabetic Molecules
Bhatta, A., Mahale, P., Baral, H., Yuvaraj, D. K., & Kaundal, R. K. (2026) · Springer eBooks · doi:10.1007/978-981-95-4522-3_3
Inhibition of daily torpor in mice requires calories, not just feeding: a potential role for GLP-1
McLear, G. M., Kakarla, A. R., Taylor, C. E., & Swoap, S. J. (2026) · Journal of Comparative Physiology B · doi:10.1007/s00360-025-01649-6
Algazzar, A. S. (2026) · Saudi Journal of Internal Medicine · doi:10.4103/sjim.sjim_12_26
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.07.030
Xu, X., Ma, F., & Yu, W. (2026) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2026.5943
Amani‐Beni, R., Darouei, B., Maleki, S., Sadri, H., Seifnezhad, A., Eshraghi, R., Bahrami, A., Ebrahimi, P., Shahid, F., Upadhyaya, S., et al. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02271-4
Zhang, T., Luo, X., Chen, C., Zhang, Y., Xu, B., He, Z., & Zhou, J. (2026) · The International Journal of Lower Extremity Wounds · doi:10.1177/15347346261487722
Alharbi, N. H. J. (2026) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70329
GLP-1 receptor agonists in cardiometabolic disease: a meta-analysis of 102,486 patients
Alwaily, Z. A., Rahman, O. U., Swe, A. T., Abouayana, A., Sodhi, N. S., Goh, M. J., Ahmed, A., Natesan, T. A., Shahzad, S., Merchant, O. H., et al. (2026) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/226416
Metadata
- Authors
- Gaspari, T., Welungoda, I., Widdop, R. E., Simpson, R. W., & Dear, A. E.
- Affiliations
- Monash University (AU)
- Eastern Health (AU)
- Venue
- Diabetes and Vascular Disease Research
- Publisher
- SAGE Publications
- Published
- 2013-05-14
- Volume
- 10
- Issue
- 4
- Pages
- 353-360
- ISSN
- 1479-1641 (ISSN-L)
- 1752-8984
- OpenAlex
- W2097575918
- Semantic Scholar
- d47930bf1bc36d35f9d29f9a8cf81aae5007f39c
- Cited by
- 148
- References
- 32
- Citations by year
- 2026: 11 · 2025: 16 · 2024: 11 · 2023: 7 · 2022: 19 · 2021: 14 · 2020: 6 · 2019: 18 · 2018: 9 · 2017: 9 · 2016: 12 · 2015: 7 · 2014: 7 · 2013: 2
- FWCI
- 7.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Diabetes and Vascular Disease Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- liraglutide, GLP-1 receptor agonists, atherosclerosis, atherosclerotic plaque stability, endothelial function, ApoE-deficient mice, cardiovascular disease prevention, weight gain, type 2 diabetes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Animals, Apolipoproteins E, Diabetes Mellitus, Type 2, Disease Models, Animal, Hypoglycemic Agents, Mice, Inbred C57BL, Receptors, Glucagon, Mice, Knockout, Disease Progression, Endothelial Cells, Atherosclerosis, Mice, Glucagon-Like Peptide 1, Plaque, Atherosclerotic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.